A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis

• Published in: Diagnostics (Basel) 2024-06, Vol.14 (12), p.1272
• Main Authors: Mima, Yoshihito, Tsutsumi, Eri, Ohtsuka, Tsutomu, Ebato, Ippei, Nakata, Yukihiro, Kubota, Taro, Norimatsu, Yuta
• Format: Article
• Language: English
• Subjects: Allergies; Atopic dermatitis; Autoimmunity; Case Report; Cataracts; Conjunctivitis; Cornea; Cyclosporine; Cytokines; Dermatitis; Disease; dupilumab; Erythema; Fibroblasts; Glaucoma; Health aspects; Histamine; Immune response; Inflammation; Kinases; Omalizumab; Oxidative stress; Pathogenesis; Phosphorylation; Steroids; T helper 2 cytokine; Tumor necrosis factor-TNF; Ulcers; upadacitinib; vernal conjunctivitis
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14121272

Vernal keratoconjunctivitis is a persistent allergic ocular disease predominantly mediated by the T-helper 2 lymphocyte-associated immune response. The standard therapeutic approaches for vernal keratoconjunctivitis include topical corticosteroids and immunosuppressive eye drops. However, managing vernal keratoconjunctivitis with only topical treatments becomes challenging during seasonally exacerbated periods. Systemic treatments such as oral corticosteroids or cyclosporine may be alternative options. Recently, dupilumab's efficacy in refractory vernal keratoconjunctivitis treatment has been documented. Here, we report a case of refractory vernal keratoconjunctivitis coexisting with atopic dermatitis that rapidly improved after upadacitinib administration. An 18-year-old Japanese woman presented with atopic dermatitis, vernal keratoconjunctivitis, and hay fever. In winter, the patient experienced widespread erythema and escalated itching, leading to significant discomfort and insomnia. Owing to the difficulty in maintaining her current regimen, upadacitinib (15 mg), a Janus kinase inhibitor was initiated. After upadacitinib administration, the treatment-resistant vernal keratoconjunctivitis and erythema improved. Upadacitinib is beneficial in severe cases of atopic dermatitis. Consequently, in our case, upadacitinib may offer therapeutic benefits for refractory vernal conjunctivitis by improving the T-helper 1/2 type immune response, autoimmunity, and oxidative stress. To our knowledge, this is the first report suggesting the potential utility of upadacitinib in managing severe vernal conjunctivitis.